Strategic Business Partnership with Moderna
Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. Their platform builds on continuous advances in mRNA science to support the development of a diverse clinical portfolio of vaccines and therapeutics.
About the Oxford-MODERNA partnership
The Business Partnerships Office works closely with Moderna’s R&D teams to support and expand collaborative research opportunities. Key areas currently include:
- Infectious Diseases & Global Health: A large number of research partnerships in this space target emerging, neglected and high-burden infectious diseases, with an emphasis on pandemic preparedness.
- Immuno-Oncology: Partnerships within oncology centre around our understanding of precancerous states and early cancer progression, the identification of novel biomarkers, and the development of innovative approaches to cancer prevention.
- mRNA Platform Science: Collaborations in mRNA platform science span fundamental and physical sciences, including research into lipid nanoparticle/mRNA technologies, formulation optimisation and delivery approaches.
Partnership Activities
- Moderna-Oxford mRNA access programme
- Research sponsored agreements
- Clinical trial agreements
- Fellowships
- DPhil studentships
Therapeutic Focus Areas
- Infectious diseases
- Immuno-oncology
- Autoimmune diseases
Partnership Manager
Related News
-
First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford
9 June 2026
Phase 1 of the INTERCEPT-Lynch trial, which is funded by Moderna, sponsored by the University of Oxford and run by the University's Oncology Clinical Trials Office with support from Oxford Cancer, has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.